Am J Transplant, Volume 5, Suppl 3 Archives - Page 75 of 170 - ATC Abstracts

2015 American Transplant Congress
Geographic Differences in HIV+ Kidney Transplant Waitlist Characteristics
J. Locke,¹ S. Gustafson,² C. Durand,³ J. Snyder,² B. Shelton,¹ R. Reed,¹ P. MacLennan,¹ S. Mehta,¹ A. Nellore,¹ D. Segev.^2,3
¹University of Alabama, Birmingham, Birmingham, AL; ²SRTR, MMRF, Minneapolis, MN; ³Johns Hopkins University, Baltimore, MD.
Kidney transplant (KT) is now a viable option for select HIV+ end-stage renal disease (ESRD) patients. As OPTN does not collect HIV status at waitlisting,…
2015 American Transplant Congress
Stem Cell and Novel Biologic Therapies to Enhance Functional Recovery in Limb Transplantation
K. Kniery, M. DeHart, T. Brown, S. Salgar.
Surgery/Clinical Investigation, Madigan Army Medical Center, Tacoma, WA.
Introduction: Unlike visceral organ transplants, vascular composite allotransplantation such as limb and face require successful nerve regeneration and reinnervation of graft motor and sensory targets…
2015 American Transplant Congress
Kidney and Liver CIT Variations Across OPOs and Their Implications: US Experience Between 2003 and 2011
J. Melancon, N. Koizumi, C. Callender, D. DasGupta, T. Smith.
Surgery, George Washington University, Washington, DC; Public Policy, George Mason University, Arlington, VA; Surgery, Howard University, Washington, DC; Health Sciences, University of Indianapolis, Indianapolis, IN; School of Engineering, University of Pennsylvania, Philadelphia, PA.
Introduction: Significant variations in kidney and liver transplant outcomes across OPOs have been reported, but their causes remain largely unknown. This study investigated variations in…
2015 American Transplant Congress
Early Clinical Indicators of Long Term Survival and Allograft Loss Following De Novo DSA. A 15-Year Longitudinal Study
M. Everly,¹ L. Rebellato,² K. Briley,² A. Maldonado,³ P. Bolin,² C. Haisch,² W. Kendrick,⁴ S. Kendrick,⁴ C. Morgan,² R. Harland,² P. Terasaki.¹
¹Terasaki Foundation, Los Angeles, CA; ²East Carolina University, Greenville, NC; ³Vidant Medical Center, Greenville, NC; ⁴Eastern Nephrology Associates, Greenville, NC.
Improvement in outcomes in renal transplant patients with de novo donor specific anti-HLA antibodies (dnDSA) is needed. This analysis aims to identify surrogate endpoints following…
2015 American Transplant Congress
Liver Transplantation for Children With Autoimmune Hepatitis and Primary Sclerosing Cholangitis: An Analysis of the UNOS Database
J. Jossen,¹ R. Annunziato,² J. Chu,¹ H.-S. Kim,² S. Sheflin,¹ J. Lai,¹ R. Arnon.¹
¹Department of Pediatrics, Mount Sinai Medical Center, New York, NY; ²Fordham University, New York.
Autoimmune hepatitis (AIH) and primary sclerosing cholangitis (PSC) are progressive immune-mediated inflammatory diseases that may require liver transplant (LT). Outcomes in children undergoing LT for…
2015 American Transplant Congress
Standardizing Quality Improvement Practices in Pediatric Liver Transplantation: The SPLIT A3 Project
B. Kelly,¹ R. Himes,² J. Bucuvalas,³ L. Ware,¹ S. Horslen.⁴
¹Surgery, Children's Hospital Pittsburgh, Pittsburgh, PA; ²Pediatrics, Texas Children's Hospital, Houston, TX; ³Pediatrics, Cincinnati Children's Hospital, Cincinnati, OH; ⁴Pediatrics, Seattle Children's Hospital, Seattle, WA; ⁵The Studies of Pediatric Liver Transplantation, EMMES Corporation, Maryland.
Quality improvement (QI) programs are key drivers of continual reform in process and patient safety, but at present, there are no pediatric liver transplant (PLT)-specific…
2015 American Transplant Congress
Does DSA Market Competition Influence OPO Performance?
J. Adler,¹ H. Yeh,¹ J. Markmann,¹ L. Nguyen,² D. Axelrod.³
¹Surgery, Massachusetts General Hospital, Boston, MA; ²Surgery, Brigham and Women's Hospital, Boston, MA; ³Surgery, Dartmouth Hitchcock Medical Center, Lebanon, NH.
INTRODUCTION: Increased market competition within a Donor Service Area (DSA) is associated with a greater number of liver and kidney transplants, but its effect on…
2015 American Transplant Congress
Living Donor Characteristics Associated With Changes in Post-Donation GFR
E. Poggio,¹ D. Mandelbrot,⁴ P. Reese,⁵ D. Goldfarb,³ S. Flechner,³ J. Schold.²
¹Nephrology and Hypertension, Cleveland Clinic, Cleveland, OH; ²Qualitative Health Sciences, Cleveland Clinic, Cleveland, OH; ³Urology, Cleveland Clinic, Cleveland, OH; ⁴Division of Medicine, University of Wisconsin, Madison, WI; ⁵Nephrology, University of Pennsylvania, Philadelphia, PA.
Living donor transplantation is the preferred modality for treatment of ESRD because it confers excellent outcomes for recipients and poses reasonable risks to most donors.…
2015 American Transplant Congress
Galectin-9 Protects Mouse Liver Transplants Against Ischemia-Reperfusion Injury
H. Ji, Y. Liu, Y. Zhang, X. Shen, F. Gao, R. Busuttil, J. Kupiec-Weglinski.
Dept of Surgery, Dumont-UCLA Liver Transplant Center, Los Angeles, CA.
Background:Although Galecin 9 (Gal-9) negatively regulates Th1-type alloimmunity by binding to T-cell Immunoglobulin Mucin-3 (TIM-3) on activated Th1 cells, its role in liver ischemia-reperfusion injury…
2015 American Transplant Congress
Activated T Regulatory Cells Escape Death by Increasing Cytoplasmic Serine Protease Inhibitor 6 (SPI6)
A. Radwan, M. Uehara, P. Lukyanchykov, L. Riella, A. Chandraker, R. Abdi, J. Azzi.
Renal/ Transplantation Research Center, Brigham and Women's Hospital, Boston, MA.
Regulatory T cells (Tregs) can employ a granzyme B (GrB)-dependent mechanism to mediate suppression of effector cells by inducing their apoptosis. In this study we…